Transdermal Delivery of Anti-Malarial Drug

This Phase I proposal is aimed to develop a technology to delivery lipophilic therapeutic ingredients in broad and antimalarial drug primaquine in specific through skins. The proposed driving force of delivering target drugs is the opposite chemical affiliation of storage copolymer matrix and active therapeutic ingredient. The technology includes the formulation of patches - hydrophilic polymers, selection of permeation enhancers, encapsulation of primaquine in the polymers and drug diffusion flux measurements. The patches will be tested in vitro with cadaver skins for primaquine release or diffusion rate in the Phase I study. In Phase II study, the tests will apply to live animals and human subjects for delivery efficiency evaluation. The key features of the proposed transdermal delivery devices are: · Effective delivery lipophilic anti-malarial drug to the skin · Controllable dosage in the preparation · Enhanced compliance for administration of soldiers · Easy to be carried with soldier and long storage life · Easy and inexpensive to be prepared · Easy to be applied by users The proposed study meets the topic narrative for DOD solicitation A04-200 "Novel Routes of Drug Administration to Enhance Compliance in Soldiers"